|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activating β-catenin mutations occur in a variety of liver tumors, including hepatocellular carcinoma (HCC), but no specific therapies are available to treat these tumor subsets.
|
30713111 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the genome-based molecular classification, CTNNB-1 mutated HCC shows a less aggressive nature, while CK19/EpCAM positive HCC and macrotrabecular massive HCC show an aggressive one.
|
30712167 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In summary, β-catenin activation promotes immune escape and resistance to anti-PD-1 and could represent a novel biomarker for HCC patient exclusion.
|
31186238 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The results of our rescue assays suggest that SOX9-AS1 regulates HCC progression through SOX9 and the Wnt/β-catenin pathway.
|
31402556 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The development of HCC involves deregulation in several cellular signalling pathways including Wnt/FZD/β-catenin, PI3K/Akt/mTOR, IRS1/IGF, and Ras/Raf/MAPK.
|
31319796 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
However, the molecular changes that link Wnt/β-catenin activation and HCC early recurrence remain poorly understood.
|
30936461 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
UNC119 promotes the growth and migration of hepatocellular carcinoma via Wnt/β/catenin and TGF/β-EMT signaling pathways.
|
29552782 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
|
30794613 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
|
30555042 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We combined a high-fat diet with a transgenic zebrafish HCC model induced by hepatocyte-specific activated beta-catenin and assessed liver size, angiogenesis, micronuclei formation and inflammation in the liver.
|
30572006 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Mechanistically, ZNF382 exerted its tumor-suppressor functions in HCC through transcriptionally repressing its downstream targets such as Fos proto-oncogene (FOS), Jun proto-oncogene (JUN), disheveled segment polarity protein 2 (DVL2), and frizzled class receptor 1 (FZD1), thereby impairing the activities of activating protein 1 (AP-1) and Wnt/β-catenin pathways and activating p53 signaling.
|
30804458 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In conclusion, through the interaction with CHMP4B and β-catenin, Vps4A regulates the PM localization and exosome sorting of β-catenin, consequently decreases β-catenin signaling, and thereby inhibits EMT and metastasis in HCC.
|
31059752 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The aberrant nucleocytoplasmic shuttling of active PTK6/β-catenin is reversed by expressing the PSPC1 C-terminal interacting domain (PSPC1-CT131), thereby suppressing PSPC1/PTK6/β-catenin-activated metastasis to prolong the survival of HCC orthotopic mice.
|
31844057 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Activation of Wnt/β-catenin pathway is a frequent event in hepatocellular carcinoma and is associated with enhanced cell survival and proliferation.
|
31440992 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Such expression profiles of β-catenin and PD-L1 in HCC may be responsible for the resistance against nivolumab treatment.
|
30996212 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
To study whether endogenous β-Catenin is required for c-Met/sgAxin1-driven HCC development, we expressed c-Met/sgAxin1 in liver-specific Ctnnb1 null mice, which completely prevented HCC development.
|
30737831 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
HBV is spreading with insane speed throughout the world and has been found a main culprit in HCC development after regulating the several cellular pathways including Wnt/β-catenin, Raf/MAPK, Akt and affecting cell multiplication to genomic instability.
|
30377095 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
This was confirmed by RT-qPCR of an independent cohort of CTNNB1-mutated HCC and the suppression of the LKB1-related profile upon β-catenin silencing of CTNNB1-mutated human hepatoma cell lines.
|
30566242 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Our studies indicate that MEISC/D promote HCC development via Wnt/β-catenin and Hippo/YAP signaling pathways, highlighting the complex molecular network of MEIS2C/D in HCC pathogenesis.
|
31623651 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
RICH2, in a Cdc42 dependent manner, regulated the formation of filopodia in HCC and stable overexpression of RICH2 significantly inhibited the clone formation, proliferation and invasion of HCC cells <i>in vitro.</i> Gene set enrichment analysis (GSEA) showed that the expression of RICH 2 positively correlated with the expression of WNT5a, that exert antagonistic effect on canonical WNT signalling whereas RICH2 expression inversely correlated with the expression of β-catenin (CTNNB1), that is involved in the proliferation and invasion HCC.
|
31136984 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In this study, we report that the expression of β-catenin and reprogramming genes p-Oct4, Nanog, Klf4, c-myc and EpCAM was significantly higher in HCC tissues compared to normal liver tissues.
|
30672133 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The miR-125b-5p/STAT3 axis inhibits the invasion, migration, and growth of HCC via inactivation of the wnt/β-Catenin pathway. miR-125b-5p-loaded nanomedicine effectively inhibits the EMT/CSC potential of hepatoma cells in vivo together with their magnetic resonance imaging (MRI) visualization characteristics.
|
31065520 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
YC-1 Antagonizes Wnt/β-Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma.
|
31086087 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
|
30953666 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Among this molecular subgroup, CTNNB1-mutated HCCs constitute a homogeneous subtype, exhibiting cholestasis and microtrabecular and pseudoglandular architectural patterns.
|
31195064 |
2019 |